Ascendis Pharma announced that its Phase 3 PaTHway Trial data show TransCon PTH maintains long-term efficacy and safety in adults with hypoparathyroidism over 182 weeks. The treatment replicated natural parathyroid hormone effects, improving quality of life and normalizing calcium and kidney function while reducing dependence on conventional therapies. 86% of patients met key treatment goals, and 89% completed the trial, with no new safety concerns. These results support TransCon PTH as a durable treatment option for this chronic condition.
Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Key contributors to this strong performance included Vertiv Holdings, Ascendis Pharma,...
Ascendis Pharma announced 5-year Phase 2 trial results for TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism. The treatment replicated natural parathyroid hormone effects, improving kidney function, calcium levels,...
Ascend Learning's ATI Engage® Series won the Digital Learning Innovation Award at the 2026 EdTech Breakthrough Awards for its advanced digital platform that enhances nursing education. The platform uses AI to personalize learning, offering interactiv...
